Apellis jumps as pegcetacoplan tops Alexion’s Soliris in PNH trial

Shares shot up more than 50% in wake of announcement. Apellis has new data showing that its pegcetacoplan drug outperformed Alexion’s market leading Soliris in rare disease paroxysmal nocturnal haemoglobinuria ... with C5 inhibitor Soliris and

Roche’s Soliris rival satralizumab scores in phase 3 study

Alexion also received European Commission approval for the extended use of Soliris in the same indication in August. ... However, both Roche and Alexion could face competition from biosimilars, as Amgen  recently filed a patent infringement action

US, EU regulators start review of Roche’s Soliris rival satralizumab

paralysis. At the moment the only approved treatment in the US is Alexion’s complement C5 inhibitor  Soliris (eculizumab), which got a green light from the FDA in June, and there ... Viela thinks inebilizumab has a dosing advantage over both Soliris

Alexion eyes Soliris combo with $930m deal to buy Achillion

paroxysmal nocturnal haemoglobinuria (PNH), a rare disease whose treatment is currently dominated by Alexion’s blockbuster complement C5 inhibitor  Soliris (eculizumab). ... combination with Soliris in PNH – and follow-up ACH-5228 in phase 1.

1 2 3 4 5 6 7 8 9 [ Next 5 results ]